Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 9.46% is 56% below its 5-year average of 21.54%, near the low end of its 5-year range (9.46%–43.54%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.03% below its 12-month average of 16.61%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 9.46%.
RETURN ON EQUITY (ROE)
9.46%
RETURN ON EQUITY (ROE) AVG TTM
16.61%
RETURN ON EQUITY (ROE) AVG 3Y
24.12%
RETURN ON EQUITY (ROE) AVG 5Y
21.54%
RETURN ON EQUITY (ROE) AVG 10Y
22.26%
RETURN ON EQUITY (ROE) AVG 15Y
21.28%
RETURN ON EQUITY (ROE) AVG 20Y
19.77%
CURRENT VS TTM AVG
-43.03%
CURRENT VS 3Y AVG
-60.77%
CURRENT VS 5Y AVG
-56.06%
CURRENT VS 10Y AVG
-57.49%
CURRENT VS 15Y AVG
-55.53%
CURRENT VS 20Y AVG
-52.14%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-27.26%
vs the sector median at left
Edwards Lifesciences Corporation
Market Cap
$49.69B
Return on Equity (ROE)
9.46%
TTM Avg
16.61%
3Y Avg
24.12%
5Y Avg
21.54%
Market Cap
$48.80B
Return on Equity (ROE)
19.56%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$50.65B
Return on Equity (ROE)
3.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$51.58B
Return on Equity (ROE)
N/A
TTM Avg
-57.79%
3Y Avg
-38.31%
5Y Avg
2.19%
Market Cap
$45.64B
Return on Equity (ROE)
9.10%
TTM Avg
-6.34%
3Y Avg
-12.86%
5Y Avg
-14.53%
Market Cap
$44.50B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$42.57B
Return on Equity (ROE)
1.09%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$40.96B
Return on Equity (ROE)
70.67%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $49.69B | 9.46% | 16.61% | 24.12% | 21.54% |
| Agilent Technologies, Inc. (A)vs › | $48.80B | 19.56% | 20.59% | 21.51% | 20.54% |
| Becton, Dickinson and Company (BDX)vs › | $50.65B | 3.85% | 6.60% | 6.50% | 6.42% |
| Humana Inc. (HUM)vs › | $47.81B | 6.65% | 7.05% | 11.93% | 15.09% |
| Cardinal Health, Inc. (CAH)vs › | $51.58B | N/A | -57.79% | -38.31% | 2.19% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $45.64B | 9.10% | -6.34% | -12.86% | -14.53% |
| IQVIA Holdings Inc. (IQV)vs › | $44.50B | 22.28% | 21.77% | 21.17% | 17.55% |
| Waters Corporation (WAT)vs › | $42.57B | 1.09% | 29.98% | 64.02% | 111.55% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.96B | 70.67% | 60.82% | 72.53% | 81.69% |
| Cencora, Inc. (COR)vs › | $59.71B | 86.03% | 168.34% | -32.99% | 148.52% |
ROE
9.5%
ROA
7.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 9.46% |
| 2026-03-31 | 10.58% |
| 2025-12-31 | 10.35% |
| 2025-09-30 | 13.37% |
| 2025-06-30 | 39.30% |
| 2025-03-31 | 41.25% |
| 2024-12-31 | 41.73% |
| 2024-09-30 | 43.54% |
| 2024-06-30 | 19.77% |
| 2024-03-31 | 19.86% |
| 2023-12-31 | 21.09% |
| 2023-09-30 | 21.49% |
| 2023-06-30 | 21.79% |
| 2023-03-31 | 24.90% |
| 2022-12-31 | 26.21% |
| 2022-09-30 | 23.46% |
| 2022-06-30 | 24.49% |
| 2022-03-31 | 26.32% |
| 2021-12-31 | 25.76% |
| 2021-09-30 | 26.66% |
| 2021-06-30 | 28.49% |
| 2021-03-31 | 18.27% |
| 2020-12-31 | 18.00% |
| 2020-09-30 | 18.86% |
| 2020-06-30 | 19.37% |
| 2020-03-31 | 28.40% |
| 2019-12-31 | 25.24% |
| 2019-09-30 | 20.28% |
| 2019-06-30 | 20.71% |
| 2019-03-31 | 22.20% |
| 2018-12-31 | 23.00% |
| 2018-09-30 | 22.34% |
| 2018-06-30 | 21.97% |
| 2018-03-31 | 18.44% |
| 2017-12-31 | 20.77% |
| 2017-09-30 | 23.55% |
| 2017-06-30 | 24.36% |
| 2017-03-31 | 23.94% |
| 2016-12-31 | 21.74% |
| 2016-09-30 | 20.50% |
| 2016-06-30 | 21.38% |
| 2016-03-31 | 22.38% |
| 2015-12-31 | 19.77% |
| 2015-09-30 | 19.14% |
| 2015-06-30 | 19.22% |
| 2015-03-31 | 39.49% |
| 2014-12-31 | 37.01% |
| 2014-09-30 | 38.06% |
| 2014-06-30 | 39.68% |
| 2014-03-31 | 22.84% |
| 2013-12-31 | 25.00% |
| 2013-09-30 | 28.18% |
| 2013-06-30 | 25.16% |
| 2013-03-31 | 23.37% |
| 2012-12-31 | 19.82% |
| 2012-09-30 | 17.26% |
| 2012-06-30 | 17.26% |
| 2012-03-31 | 17.11% |
| 2011-12-31 | 17.69% |
| 2011-09-30 | 17.60% |
| 2011-06-30 | 16.95% |
| 2011-03-31 | 17.25% |
| 2010-12-31 | 16.66% |
| 2010-09-30 | 16.28% |
| 2010-06-30 | 20.25% |
| 2010-03-31 | 18.78% |
| 2009-12-31 | 19.79% |
| 2009-09-30 | 20.14% |
| 2009-06-30 | 17.84% |
| 2009-03-31 | 18.15% |
| 2008-12-31 | 14.67% |
| 2008-09-30 | 12.19% |
| 2008-06-30 | 11.46% |
| 2008-03-31 | 12.60% |
| 2007-12-31 | 13.53% |
| 2007-09-30 | 14.31% |
| 2007-06-30 | 14.44% |
| 2007-03-31 | 15.01% |
| 2006-12-31 | 17.43% |
| 2006-09-30 | 20.40% |
| 2006-06-30 | 16.10% |
| 2006-03-31 | 13.00% |
| 2005-12-31 | 11.49% |
| 2005-09-30 | 10.10% |
| 2005-06-30 | 12.60% |
| 2005-03-31 | 14.66% |
| 2004-12-31 | 0.27% |
| 2004-09-30 | -0.88% |
| 2004-06-30 | 1.16% |
| 2004-03-31 | 0.42% |
| 2003-12-31 | 12.44% |
| 2003-09-30 | 14.14% |
| 2003-06-30 | 7.14% |
